Reuters logo
BRIEF-Janssen says Phase 3 data shows anti-TNF Alpha Simponi Aria significantly improved arthritis, skin manifestations
June 14, 2017 / 11:17 AM / 3 months ago

BRIEF-Janssen says Phase 3 data shows anti-TNF Alpha Simponi Aria significantly improved arthritis, skin manifestations

June 14 (Reuters) - Janssen:

* New phase 3 data show anti-TNF alpha simponi aria significantly improved arthritis and skin manifestations in patients with active psoriatic arthritis

* Janssen- ‍simponi aria showed significant improvement across all secondary endpoints evaluating improvements in skin symptoms, joint damage, among others​

* Janssen - in go-vibrant, 75.1 percent of patients with active psoriatic arthritis with simponi aria 2 mg/kg achieved at least 20 percent improvement in arthritis signs

* Janssen- ‍treatment with simponi aria at weeks 0 & 4,every 8 weeks thereafter resulted in statistically significant improvements in all secondary goals​

* Janssen - two deaths and two malignancies were reported, all in placebo group, and one demyelinating event occurred in simponi aria group Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below